BRIEF-3SBio Says Unit Entered Exclusive Commercialization Cooperation Agreement

Reuters
24 Oct 2024

Oct 24 (Reuters) - 3SBio Inc :

* UNIT ENTERED INTO PACLITAXEL ORAL SOLUTION EXCLUSIVE COMMERCIALIZATION COOPERATION AGREEMENT

* COOPERATION AGREEMENT WITH SHANGHAI HAIHE BIOPHARMA RESEARCH AND DEVELOPMENT, OTHERS

* SHENYANG SUNSHINE WILL OBTAIN EXCLUSIVE COMMERCIALIZATION RIGHTS OF RMX BIOPHARMA'S PRODUCT OF PACLITAXEL ORAL SOLUTION

Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10